Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,issuanceOfStock,otherCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,exchange,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,marketState,market,shortName,exchangeDataDelayedBy,esgPopulated,tradeable,priceHint,regularMarketChangePercent,regularMarketDayRange,epsTrailingTwelveMonths,epsForward,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,EPGNF,3812000.0,5891230,247000,,-2573000,,-2577000,1859000,270000,-1051000,-1051000,-785000,-12000,,,,4000,301000,1352000,31000,-1522000,,-2577000,-2577000,52000.0,2933000.0,3864000.0,92000.0,382000.0,6797000.0,5891000.0,32000.0,-90732000.0,36000.0,88705000.0,92000.0,3566000.0,2437000.0,88705000.0,1184000.0,5469000.0,961000.0,474000.0,122000.0,629000.0,606000.0,-4000.0,-78000.0,-72000.0,-209000.0,-2169000.0,-23000.0,-21000.0,-2072000.0,-61000.0,70000.0,-161000.0,29000.0,67000.0,-4000.0,,,3032000.0,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,1.32,1629227445,0.0,1.32,1.32,1.32,25,1.32,0.0,0.0,0,0,finmb_136714,Other OTC,Epigenomics AG,EUR,178,0,0.88000005,2.0000002,0.44 - 6.84,-5.52,-0.8070175,0.44,6.84,REGULAR,us_market,EPIGENOMICS AG,0,False,False,4,0.0,1.32 - 1.32,-2.438,-0.21,0.656,1.4355556,-0.115555525,-0.080495335,1.9841304,-0.66413033,-0.33472112,7105006,-6.2857146,2.012195,15,America/New_York,EDT,-14400000,1.06,,,6.84,0.44,1.4356,1.9841,178,,5.89M,,1.94M,36.33%,15.97%,,,,,,,,,,,0.00%,,,1:8,"Dec 10, 2020","Dec 30, 2020","Dec 30, 2020",0.00%,"-1,201.19%",-60.82%,-173.22%,842k,0.15,8.30%,697k,-10.01M,-11.69M,-2.4380,,4.53M,0.77,683k,17.68,2.24,0.66,-9.57M,-6.25M,Value,10829,Healthcare,37,"Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",Berlin,49 30 243 450,1609372800,Germany,http://www.epigenomics.com,86400,Geneststrasse 5,49 30 2434 5555,Diagnostics & Research
t-1,EPGNF,5353000.0,5891230,658000,,-2750000,,-2754000,1540000,176000,-2022000,-2022000,-785000,-13000,,,,4000,219000,2241000,43000,-728000,,-2754000,-2754000,191000.0,3286000.0,5544000.0,,1941000.0,8830000.0,47130000.0,436000.0,-111936000.0,44000.0,70350000.0,,5735000.0,2723000.0,70350000.0,1275000.0,7364000.0,905000.0,91000.0,197000.0,557000.0,402000.0,1000.0,-67000.0,-95000.0,42000.0,-2074000.0,-23000.0,3000.0,-1983000.0,129000.0,42000.0,-34000.0,-28000.0,191000.0,1000.0,,,4641000.0,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,1.32,1629227445,0.0,1.32,1.32,1.32,25,1.32,0.0,0.0,0,0,finmb_136714,Other OTC,Epigenomics AG,EUR,178,0,0.88000005,2.0000002,0.44 - 6.84,-5.52,-0.8070175,0.44,6.84,REGULAR,us_market,EPIGENOMICS AG,0,False,False,4,0.0,1.32 - 1.32,-2.438,-0.21,0.656,1.4355556,-0.115555525,-0.080495335,1.9841304,-0.66413033,-0.33472112,7105006,-6.2857146,2.012195,15,America/New_York,EDT,-14400000,1.06,,,6.84,0.44,1.4356,1.9841,178,,5.89M,,1.94M,36.33%,15.97%,,,,,,,,,,,0.00%,,,1:8,"Dec 10, 2020","Dec 30, 2020","Dec 30, 2020",0.00%,"-1,201.19%",-60.82%,-173.22%,842k,0.15,8.30%,697k,-10.01M,-11.69M,-2.4380,,4.53M,0.77,683k,17.68,2.24,0.66,-9.57M,-6.25M,Value,10829,Healthcare,37,"Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",Berlin,49 30 243 450,1609372800,Germany,http://www.epigenomics.com,86400,Geneststrasse 5,49 30 2434 5555,Diagnostics & Research
t-2,EPGNF,7230000.0,5891230,1151000,,-3367000,,-3373000,1908000,68000,-2976000,-2976000,-15000,-14000,,,,6000,83000,3059000,15000,-391000,,-3373000,-3373000,87000.0,3724000.0,7317000.0,152000.0,671000.0,11041000.0,47130000.0,23000.0,-109181000.0,44000.0,69368000.0,152000.0,7809000.0,3099000.0,69368000.0,1367000.0,9435000.0,854000.0,281000.0,241000.0,906000.0,906000.0,18000.0,-55000.0,-214000.0,-194000.0,-2443000.0,-23000.0,-3000.0,-2244000.0,137000.0,48000.0,19000.0,-555000.0,212000.0,1000.0,396000.0,18000.0,6336000.0,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,1.32,1629227445,0.0,1.32,1.32,1.32,25,1.32,0.0,0.0,0,0,finmb_136714,Other OTC,Epigenomics AG,EUR,178,0,0.88000005,2.0000002,0.44 - 6.84,-5.52,-0.8070175,0.44,6.84,REGULAR,us_market,EPIGENOMICS AG,0,False,False,4,0.0,1.32 - 1.32,-2.438,-0.21,0.656,1.4355556,-0.115555525,-0.080495335,1.9841304,-0.66413033,-0.33472112,7105006,-6.2857146,2.012195,15,America/New_York,EDT,-14400000,1.06,,,6.84,0.44,1.4356,1.9841,178,,5.89M,,1.94M,36.33%,15.97%,,,,,,,,,,,0.00%,,,1:8,"Dec 10, 2020","Dec 30, 2020","Dec 30, 2020",0.00%,"-1,201.19%",-60.82%,-173.22%,842k,0.15,8.30%,697k,-10.01M,-11.69M,-2.4380,,4.53M,0.77,683k,17.68,2.24,0.66,-9.57M,-6.25M,Value,10829,Healthcare,37,"Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",Berlin,49 30 243 450,1609372800,Germany,http://www.epigenomics.com,86400,Geneststrasse 5,49 30 2434 5555,Diagnostics & Research
t-3,EPGNF,5984000.0,5891230,1603000,,-2974000,,-2982000,1992000,182000,-3413000,-3413000,-15000,-15000,,,,8000,239000,3652000,57000,439000,,-2982000,-2982000,288000.0,7279000.0,6272000.0,,5607000.0,13551000.0,43528000.0,456000.0,-105808000.0,45000.0,68552000.0,,10252000.0,6592000.0,68552000.0,1460000.0,11803000.0,731000.0,73000.0,291000.0,760000.0,-1420000.0,-12000.0,-68000.0,3363000.0,755000.0,97000.0,-23000.0,18000.0,-3272000.0,137000.0,25000.0,17000.0,-171000.0,196000.0,-7000.0,3602000.0,6000.0,5211000.0,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,1.32,1629227445,0.0,1.32,1.32,1.32,25,1.32,0.0,0.0,0,0,finmb_136714,Other OTC,Epigenomics AG,EUR,178,0,0.88000005,2.0000002,0.44 - 6.84,-5.52,-0.8070175,0.44,6.84,REGULAR,us_market,EPIGENOMICS AG,0,False,False,4,0.0,1.32 - 1.32,-2.438,-0.21,0.656,1.4355556,-0.115555525,-0.080495335,1.9841304,-0.66413033,-0.33472112,7105006,-6.2857146,2.012195,15,America/New_York,EDT,-14400000,1.06,,,6.84,0.44,1.4356,1.9841,178,,5.89M,,1.94M,36.33%,15.97%,,,,,,,,,,,0.00%,,,1:8,"Dec 10, 2020","Dec 30, 2020","Dec 30, 2020",0.00%,"-1,201.19%",-60.82%,-173.22%,842k,0.15,8.30%,697k,-10.01M,-11.69M,-2.4380,,4.53M,0.77,683k,17.68,2.24,0.66,-9.57M,-6.25M,Value,10829,Healthcare,37,"Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",Berlin,49 30 243 450,1609372800,Germany,http://www.epigenomics.com,86400,Geneststrasse 5,49 30 2434 5555,Diagnostics & Research
